Genetic Technologies Limited (ASX:GTG, NASDAQ:GENE) has published another research paper supporting the utilisation of its ‘geneType’ breast cancer risk assessment test in the peer-reviewed journal Cancer Prevention Research.
This study is the third paper accepted for publication in the last six months that highlights the utility of the geneType breast cancer risk assessment test as a powerful risk stratification tool available to the general population.
GTG director of clinical and medical affairs Dr Erika Spaeth, who is also the lead author on the paper, noted: “This publication highlights the potential utility of a risk stratification tool able to be used on the general population.
“There are a significant number of women that are identified as at-increased risk by geneType and these same women ‘fly under the radar’ if traditional clinical models are used.”
Improved performance compared to gold-standard model
The published paper entitled: Validation of an abridged breast cancer risk prediction model for the general population, reported results from an extensive study undertaken by the GTG scientific team in collaboration with professor John Hopper from the Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne.
GeneType improved discrimination and risk categorization when compared to one of the most well-known models, the Breast Cancer Risk Assessment Tool (BCRAT).
Over a five-year period, at-risk women classified ≥3% 5-year risk by geneType had a 1.829 times increased incidence of breast cancer compared to the general population, which was higher than the 1.413 times increased incidence for women classified ≥3% by BCRAT.
“Another key milestone for the company”
GTG CEO Simon Morriss said: “This is another key milestone for the company highlighting our commitment to clinical and scientific validation of the geneType platform.
“The publication of this study in combination with the Nurses’ Health Study, provides considerable evidence of utility for our discussions with US Payers and, importantly, in gaining additional traction to initiate a pilot study with one or more of these Payers.”